---
title: "U.S. Stock Market Midday Update: Soligenix down 7.29%"
description: "Soligenix fell 7.29%; Gilead Sciences rose 9.01%, with a trading volume of USD 760 million; Fortress Biotech fell 2.06%, with a trading volume of USD 652 million; Natera rose 11.03%, with a trading vo"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252274393.md"
published_at: "2025-08-08T17:22:40.000Z"
---

# U.S. Stock Market Midday Update: Soligenix down 7.29%

> Soligenix fell 7.29%; Gilead Sciences rose 9.01%, with a trading volume of USD 760 million; Fortress Biotech fell 2.06%, with a trading volume of USD 652 million; Natera rose 11.03%, with a trading volume of USD 334 million; AbbVie rose 0.10%, with a market capitalization of USD 351.6 billion

**U.S. Stock Market Midday Update**

Soligenix fell 7.29%, with increased trading volume. Based on recent important news:

1.  On August 6, Soligenix's financial report showed a net income of negative, with a basic earnings per share of -$0.77, leading to a 7.29% drop in stock price.
    
2.  On August 5, Soligenix's product revenue fell short of expectations, raising market concerns about its future growth, further depressing the stock price.
    
3.  On August 7, International Business Settlement's stock price rose 30.54%, attracting market attention and diverting investment interest away from Soligenix.
    

**Stocks with High Trading Volume in the Industry**

Gilead Sciences rose 9.01%, with a trading volume of $760 million. Based on recent important news:

1.  On August 8, Gilead Sciences released its Q2 2025 financial report, showing a 2% year-over-year increase in total revenue to $7.1 billion, in line with market expectations, with a pre-market stock price increase of 2.9%.
    
2.  On August 8, Gilead Sciences raised its full-year revenue and earnings guidance, expecting adjusted earnings per share to be between $7.95 and $8.25, higher than previously expected.
    
3.  On August 9, Truist upgraded Gilead Sciences' rating from hold to buy and raised the target price from $108 to $127, with the stock price increasing by 8.3%.
    

Forty Pharmaceuticals fell 2.06%, with a trading volume of $652 million. Based on recent key news:

1.  On August 8, Forty Pharmaceuticals' VX-993 failed to show significant pain relief effects in Phase II clinical trials, leading to an 18.8% drop in stock price.
    
2.  On August 7, board member BRUCE SACHS made significant internal purchases, showing confidence in the company's future.
    
3.  On August 6, analysts from RBC Capital and Scotiabank lowered the target price for Forty Pharmaceuticals, from $430 to $405 and from $442 to $438, respectively.
    

Natera rose 11.03%, with increased trading volume. Based on recent important news:

1.  On August 8, Natera reported record quarterly revenue and raised its annual revenue and gross margin guidance, driving the stock price up by 11.03%.
    
2.  On August 8, Natera's short interest ratio decreased by 41.44%, boosting market confidence in the company's prospects.
    
3.  On August 8, multiple institutions raised Natera's target price, further enhancing market sentiment.
    

**Stocks with High Market Capitalization in the Industry**

AbbVie rose 0.10%, with increased trading volume. Based on recent important news:

1.  On August 8, AbbVie raised its full-year guidance, with significant growth in Skyrizi in the psoriasis and IBD fields, boosting market confidence and increasing stock price
    
2.  On August 6, AbbVie acquired Gilgamesh Pharmaceuticals to expand its market for mental disorder medications and enhance the company's competitiveness.
    
3.  On August 5, AbbVie set a sales target of $24 billion, with no significant patent cliffs in the coming years, and market expectations are optimistic

### Related Stocks

- [SNGX.US - Soligenix](https://longbridge.com/en/quote/SNGX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Soligenix 为股东提供关于罕见病研发管线的最新更新 | Soligenix（SNGX）于 2026 年 2 月 12 日发布了股东更新，详细介绍了其罕见疾病管线的进展，包括针对皮肤 T 细胞淋巴瘤的第三阶段 FLASH2 试验，目前已招募 66 名患者，目标为 80 名。公司报告了 SGX945 | [Link](https://longbridge.com/en/news/275812846.md) |
| Soligenix 在新的公司介绍中展示了其罕见病研发管线和市场潜力 | Soligenix Inc. 发布了一份企业演示文稿，详细介绍了其在罕见疾病治疗方面的进展，包括针对皮肤 T 细胞淋巴瘤的 HyBryte (SGX301)，该药物已显示出积极的三期临床试验结果。该管线还包括用于银屑病的 SGX302 和用 | [Link](https://longbridge.com/en/news/271950396.md) |
| 根据顶级分析师的建议，2026年2月12日，有 3 只 “强力买入” 股票值得现在购买 | 华尔街顶级分析师推荐三只股票作为 “强力买入”：Fennec Pharmaceuticals（FENC），目标价为 16 美元，意味着上涨空间为 83.77%；LightPath Technologies（LPTH），修正后的目标价为 15 | [Link](https://longbridge.com/en/news/275777502.md) |
| Soligenix 银屑病试验的扩展研究显示新型凝胶取得更好效果 | Soligenix 宣布了 SGX302 凝胶在银屑病治疗中的积极 2a 期扩展结果，显示出皮肤评分改善和良好的耐受性。新的凝胶配方增强了使用的便利性，且未报告不良事件。一名患者达到了 “几乎清晰” 的状态，PASI 评分显著改善。该凝胶的 | [Link](https://longbridge.com/en/news/270050898.md) |
| Soligenix 公布了 SGX945 用于白塞氏病的 IIa 期试验数据 | Soligenix 公布了 SGX945 在治疗贝赫切特病的 IIa 期临床试验的积极结果，显示患者的溃疡和疼痛有所减少。该研究将 SGX945 与阿普米司进行了比较，显示出相似的疗效且副作用更少。Soligenix 计划对 SGX945  | [Link](https://longbridge.com/en/news/270290059.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.